Abstract • 189
41 children(age 11 mo-15 years) with marphocytochemically confirmed AML(FAB M0-M5) were identically treated according to protocol mBFM-87. Most of patients received treatment before 1993, so median folloup was 52,51 mo. Bone marrow leukemic cells from all patients were immunophenotyped for myeloid(CD11b,CD13,CD14,CD15,CD33),B-lineage(CD19,CD22,CD37),T-lineage (CD1a, CD2, CD3, CD4, CD5, CD7), erythroid (erythroblastic antigen, glycophorine A) and other antigens (CD10, CD38, CD34, HLA-DR). Prognosis was estimated according to standard criteria: disease-free survival(DFS), event-free survival(EFC) and overall survival(OS). Myeloid antigen expression did not influences on DFS, EFS and OS. Expression of T-cell antigens was associated with longer DFS(p=0,02), as well as longer OS.
B-cell antigen expression negatively influences the prognosis: shorter DFS(p=0,04) The most important immunological prognostic factor was the expression of HLA-DR: HLA-DR-negative group had the most favorite disease outcome-EFS,OS,DFS(p=0,006). The last finding is of course partially associated with HLA-DR -negativity in M3-variant. So, our data confirmed the prognostic importance of some immunological markers in childhood AML treated according to modern intensive chemotherapy programmer.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mayakova, S., Popa, A., Tupitsin, N. et al. Immunological prognostic markers in childhood AML. Pediatr Res 45 (Suppl 5), 774 (1999). https://doi.org/10.1203/00006450-199905010-00219
Issue Date:
DOI: https://doi.org/10.1203/00006450-199905010-00219